Abstract
Background Lung adenocarcinoma (LUAD) is the most common malignant neoplasm with a poor 5-year survival rate (<16%). Ferroptosis, an iron-dependent cell death mechanism, has emerged as a key regulator of tumor progression, yet its clinical relevance in LUAD remains unclear. This study aimed to explore ferroptosis-related genes (FRGs) as diagnostic and prognostic biomarkers for LUAD.
Methods Differentially expressed genes (DEGs) were identified from TCGA (526 LUAD vs. 59 normal) and GEO (GSE31210, 226 LUAD) datasets. Hub FRGs were selected via intersection of DEGs and FerrDb V2 genes, followed by survival analysis. Diagnostic models were built using SVM with ten-fold cross-validation, while prognostic signatures were developed through LASSO Cox regression. Immune infiltration (CIBERSORT) and functional enrichment (GO/KEGG) analyses were performed. ELAVL1 and SLC7A11 were validated by IHC in tissues and siRNA knockdown in PC9 cells.
Results The two-gene diagnostic model (ELAVL1 + SLC7A11) achieved high accuracy (AUC = 0.9675). High-risk patients (elevated ELAVL1/SLC7A11) showed poorer overall survival (median OS: 32.1 vs. 48.6 months, HR = 1.78, P < 0.001). Functional enrichment revealed cell cycle dysregulation and immune activation in high-risk groups. ELAVL1 knockdown suppressed LUAD cell proliferation/migration and downregulated CDK4/6.
Conclusion ELAVL1 serves as a dual-functional biomarker for LUAD diagnosis and prognosis, mechanistically linking ferroptosis to immune evasion and cell cycle progression. The two-gene signature provides a robust tool for clinical risk stratification, highlighting ELAVL1 as a potential therapeutic target.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The research was approved by the Ethics Committee of The First People's Hospital of Zhaoqing City (Approval No.: Ethical review of The First People's Hospital of Zhaoqing City 2021-06-06).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data used in this study include third-party data from publicly accessible repositories (TCGA: https://portal.gdc.cancer.gov/ GEO: https://www.ncbi.nlm.nih.gov/geo/)
http://www.zhounan.org/ferrdb/
